|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
Cambridge,MA,US
|
|
At Zumutor, we are on a mission to develop novel novel immuno onco-therapeutics that drive transformational improvements in cancer treatment through NK cell engagement. We leverage our proven proprietary antibody discovery- INABLRâ„¢ for fast track Antibody discovery and development.
Our team works in collaboration with a world class Scientific Advisory Board with expertise in immuno-oncology and clinical development. Our lead asset (ZM008) is a first-in-class antibody that targets certain receptors that blocks NK cell inhibitory signal and enables NK cell activation to generate a potent immune response. Development is on track for an IND filing by Q2 2022 and Phase 1 clinical trial thereafter.
We are headquartered in CIC Cambridge Campus, MA and R&D is carried out at ISO certified lab in Bangalore, India
|
Zumutor Biologics Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Zumutor Biologics email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Zumutor Biologics customer service number in your country click here to find.
Sejeli Kath Rengma is the CEO of Zumutor Biologics.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.